EGFR and colorectal carcinoma: Moving to the resistance to combined EGFR + KRAS G12C blockade in CRC, even in this case most mechanisms converge on RAS-MAPK pathway reactivation either by de novo mutations or by parallel signaling through other RTKs [90].